Lipocine is trading at $1.83, down 5.14%; the cause of the October 9 decline remains unclear.

  • No reliable report identified a specific reason, and no company-specific catalyst has been confirmed. The latest company announcement was Health Canada’s October 7 approval of TLANDO, with a Canadian launch planned by year-end.
  • Broad indexes are higher, and the supplied biotech-sector context is positive; neither clearly accounts for the decline.